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Abstract
Background: SNP309 T/G (rs2279744) causes higher levels of MDM2, the most important negative
regulator of the p53 tumor suppressor. SNP72 G/C (rs1042522) gives rise to a p53 protein with a greatly
reduced capacity to induce apoptosis. Both polymorphisms have been implicated in cancer. The SNP309
G-allele has recently been reported to accelerate diffuse large B-cell lymphoma (DLBCL) formation in pre-
menopausal women and suggested to constitute a genetic basis for estrogen affecting human
tumorigenesis. Here we asked whether SNP309 and SNP72 are associated with DLBCL in women and are
correlated with age of onset, diagnosis, or patient's survival.
Methods: SNP309 and SNP72 were PCR-genotyped in a case-control study that included 512 controls
and 311 patients diagnosed with aggressive NHL. Of these, 205 were diagnosed with DLBCL.
Results: The age of onset was similar in men and women. The control and patients group showed similar
SNP309 and SNP72 genotype frequencies. Importantly and in contrast to the previous findings, similar
genotype frequencies were observed in female patients diagnosed by 51 years of age and those diagnosed
later. Specifically, 3/20 female DLBCL patients diagnosed by 51 years of age were homozygous for SNP309
G and 2/20 DLBCL females in that age group were homozygous for SNP72 C. Neither SNP309 nor SNP72
had a significant influence on event-free and overall survival in multivariate analyses.
Conclusion:  In contrast to the previous study on Ashkenazi Jewish Caucasians, DLBCL in pre-
menopausal women of central European Caucasian ethnicity was not associated with SNP309 G. Neither
SNP309 nor SNP72 seem to be correlated with age of onset, diagnosis, or survival of patients.
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Background
The p53 tumor suppressor can drive stressed cells into
senescence or apoptosis. One of the key negative regula-
tors that keeps p53 in check in unstressed cells and limits
p53's response under stress is the E3 ubiquitin ligase
MDM2 [1]. A disequilibrium in the levels of MDM2 and
p53 is associated with distinct phenotypes. For example,
reduction of MDM2 expression in mice reduces adenoma
formation [2] whereas MDM2 deficiency causing over-
shooting p53 activity was reported to be lethal [3,4]. On
the other hand, overproduction of MDM2 is accompanied
by a reduction of p53 activity and is a hallmark of some
tumor types in humans [5-7]. Thus, inherited differences
in the efficacy of the MDM2-mediated limitation of p53-
response in stressed cells could be important determi-
nants of efficient tumor suppression [8].
Intracellular MDM2 expression is controlled at the levels
of protein stability, gene transcription, and transcript
translation [1]. Upon stress or hormonal signalling, vari-
ous transcription factors, among them p53 and the estro-
gen receptor ER-α [9] bind to response elements of the
MDM2  gene promoter in the first intron. As a result,
MDM2 levels rise and p53 activity is limited. Work by
Bond and colleagues [10-12] has recently indicated that a
single nucleotide polymorphism at intron 1 position 309
(rs2279744) generates a novel binding site for the ubiqui-
tous transcriptional activator SP1 and causes higher
MDM2 levels and consequently, attenuated p53 response
in stressed or estrogen-exposed cells.
The p53 allele with a "C" instead of "G" at position 12139
(SNP72 C; rs1042522), coding for proline instead of
arginine at amino acid position 72, occurs at a frequency
of approximately 23% among Caucasians and is consid-
ered to be associated with at least some types of cancers
[13]. Observations by Hong and colleagues suggest that
homozygosity for both SNP309 G and SNP72 C can be
additive [14]. The present study analyzes both polymor-
phisms in 311 patients with B-NHL and 512 healthy cen-
tral Europeans of Caucasian ethnicity.
Methods
Study population
The cohort consisted of 311 patients from whom genomic
DNA-samples were available that had biopsy-confirmed,
aggressive NHL according to the Revised European-Amer-
ican Lymphoma Classification (translated into the World
Health Organisation classification) and were treated in
the NHL-B1 and B2 study [15,16] of the German High
Grade Non-Hodgkin's lymphoma study group (DSH-
NHL). A subgroup of these patients was diagnosed with
diffuse-large B-cell lymphoma (DLBCL; n = 205). Patients
were excluded from the study if the diagnosis of aggressive
or very aggressive lymphoma was not confirmed or if the
diagnosis was changed into indolent lymphoma or no
lymphoma at all by a panel of five expert hematopatholo-
gists in a blinded central pathology review. Other criteria
for exclusion are summarized elsewhere [15,16]. Table 1
outlines the clinico-pathological characteristics and table
2 the histopathological diagnoses of the patients. Blood
donors (n = 512) from the Institute for Transfusion Med-
icine, University of Saarland Medical School, served as
controls. DNA from patients diagnosed with B-NHL was
collected at the University of Göttingen during the study
period.
DNA extraction and genotyping
Genomic DNA was isolated from whole blood with the
QIAamp Blood Kit (Qiagen, Hilden). DNA was diluted in
water to a final concentration of 15 ng/µl to use 5 µl (45
ng) per reaction. The mutation tests were performed in the
LightCycler 1.2 (p53) or LightCycler 480 (MDM2) instru-
ment, using the FastStart DNA Master Hybridization
Probes kit with 3 mM MgCl2 (Roche Diagnostics, Man-
nheim) in a total volume of 20 µl, and analyzing the melt-
ing curve of the hybridization probes releasing from the
PCR product. The analysis for the p53 codon 72 mutation
was performed as described [17]. For the detection of the
Mdm2 polymorphism rs2279744, we used 0.5 µM of the
the primers mdmFmt  5'ggCTgCggggCTgCT-3'(position
2565–2579 in Genbank AF527840), changing base
2575C to T (underlined), and primer mdmR 5'-CCAATC-
CCgCCCAgACTAC-3'(2611–2637), plus 0,25 µM of the
detection probes, consisting of the 3'-terminal fluores-
cein-labeled Sensor(T) CTgCTTCggCgCg_gATgATCgCAg–
FL (position 2575(---)2607), specific for the T allele
(underlined) also containing the base 2575T and a gap for
the target sequence positions 2588–2596, and the 5'-
LightCycler Red 640 labeled and 3'-phosphorylated
anchor probe 640-CCTgTCgggTCACTAgTgTgAACgCTg–
PH (2611–2637)(TIB MOLBIOL, Berlin). After an initial
denaturation at 95°C for 12 min 30 s, amplification was
performed using 45 cycles of denaturation (95°C, 5 sec,
ramp rate 4.4°C), annealing (60°C, 10 sec, ramp rate
2.2), and extension (72°C, 20 sec, ramp rate 4.4°C). Flu-
orescence was measured at the end of the annealing
period of each cycle. After the amplification a melting
curve was generated: the PCR mixture was heated to 95°C
for 20 sec, ramp rate 4.4°C/s, cooled to 40°C, 20 sec,
ramp rate 1.5°C/sec and then slowly heated to 85°C with
one acquisition per °C. The fluorescence signal was mon-
itored continuously during the temperature ramp and
then plotted against the temperature. These curves were
transformed to derived melting curves (-d(F2)/dT vs. T).
Design of MDM2 detection probes
The MDM2 target sequence is extremely rich in strong GC
bases (70%). This is known to cause difficulties in PCR
amplification. In particular, we found stem loop CCGC–BMC Cancer 2008, 8:116 http://www.biomedcentral.com/1471-2407/8/116
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Table 1: Clinico-pathological characteristics of the patients
analyzed
Patients characteristics all trial patients B 1/2 (n = 1399) NHL patients (n = 311) DLBCL patients (n = 205)
Age Median; yr (range) 75) 60 (18–75) 62 (23–75) 61 (23–75)
Sex
male 789 (56%) 175 (56%) 115 (56%)
female 610 (44%) 136 (44%) 90 (44%)
International Prognostic Index (IPI)
Low (0,1) 840 (60%) 176 (57%) 118 (58%)
Low intermediate (2) 250 (18%) 62 (20%) 42 (20%)
High intermediate (3) 170 (12%) 46 (15%) 31 (15%)
High (4,5) 139 (10%) 27 (9%) 14 (7%)
Risk Age
Age ≤ 60 yrs 710 (51%) 143 (46%) 98 (48%)
Age > 60 yrs 689 (49%) 168 (54%) 107(52%)
Risk extranodal involvement
≤ 1 ex. involvement 1123 (80%) 254 (82%) 174(85%)
> 1 ex. involvement 276 (20%) 57 (18%) 31(15%)
Risk ECOG
ECOG 0,1 1236 (88%) 273 (88%) 178(87%)
ECOG 2–4 163 (12%) 38 (12%) 27(13%)
Risk Stage
Stage I, II 832 (59%) 191 (61%) 134(65%)
Stage III-IV 567 (41%) 120 (39%) 71(35%)
Risk LDH
LDH ≤ ONW 1083 (77%) 241 (77%) 160(78%)
LDH > ONW 316 (23%) 70 (23%) 45(22%)
Bulky tumor (7.5 cm or larger) 467 (33%) 90 (29%) 62(30%)
Table 2: Histopathological characteristics
number (%) Histopathological diagnosis (REAL-classification)
284 91.32 B-cell lymphomas
205 65.92 Diffuse large B-cell lymphoma
13 4,18 DLBCL, NOS
8 2.57 anaplastic large-cell (ALC)
46 14.79 centroblastic diffuse, NOS
16 5.14 centroblastic diffuse, NOS -> monomorphic
9 2.89 centroblastic diffuse, NOS -> multi-lobulated
89 28.62 centroblastic diffuse, NOS -> polymorphic
17 5.47 immunoblastic
4 1.29 primary mediastinal B-cell lymphoma
3 0.96 T-cell rich B-cell-lymphoma
79 25.40 Non-DLBCL B-cell lymphomas
15 4.82 centroblastic-follicular
6 1.93 centroblastic follicular and diffuse
4 1.29 mantle-cell blastic variant
3 0.96 Burkitt-lymphoma
12 3.86 high-grade Burkitt-like
5 1.61 blastic marginal-zone
16 5.14 not otherwise specified
18 5.79 unclassified (technical reasons)
27 8.68 T-cell lymphomas
20 6.43 anaplastic large-cell
4 1.29 peripheral NOS -> small and large-cell
1 0.32 T-cell-lymphoma (AILD)
2 0.64 not otherwise specifiedBMC Cancer 2008, 8:116 http://www.biomedcentral.com/1471-2407/8/116
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GCGG, spanning the polymorphism, to have a Tm of
82°C (OLIGO 6.0, MBI). This stem loop was excluded
from the PCR fragment by introduction of one base sub-
stitution C2575T which had to be changed also in the sen-
sor probe. The segment around the mutated base contains
only G and C bases (85%), making a probe based analysis
difficult. A very short probe will fail to bind the mis-
matched allele whereas a longer probe will reach
extremely high binding temperatures, causing poor differ-
entiation of the variants in the melting curve analysis. To
overcome these difficulties we followed the procedures of
[18], introducing a 9 nucleotides gap ggaggtccg in the sen-
sor probe, resulting in a 24 mer sequence with a GC con-
tent of 67%.
Statistical analysis
Out of the NHL B1/2 trial patients, 311 DNA samples
were available for analysis. The allelic frequencies were
compared with Fisher's exact test. Mann-Whitney U test
was used to test for differences among the onset of NHL
by age. Event-free survival (EFS) was defined as the time
from the beginning of therapy to either disease progres-
sion; initiation of salvage therapy; or additional (off-pro-
tocol) treatment, relapse, or death. Overall survival (OS)
was defined as the time from first day of treatment to
death from any cause. In EFS and OS analyses, a Cox mul-
tivariate analysis was done to adjust for known adverse
risk factors, defined by the International Prognostic Index
IPI, and additionally, for bulky disease (tumors > 7.5 cm
anywhere). EFS and OS were estimated with the Kaplan-
Meier method and were compared with the log-rank test.
Differences between groups were regarded as significant
for p values less than 0.05 (two-sided). Statistical analyses
were performed with R 2.5.1. [19].
Results
MDM2 gene SNP309 T/G
Among the 311 patients diagnosed with NHL, no differ-
ence in the onset by age between genders was detectable
(p = 0.33). Specifically, male patients were diagnosed, on
average, at the age of 58 years (range: 23–75 years) and
female patients at the age of 59 years (range: 24–75
years)(Fig. 1). Similarly, in the subgroup of 205 patients
diagnosed with DLBCL, no difference in the onset by age
was detectable (p = 0.18). Men were diagnosed at the age
of 57 years (range: 23–75 years) and women at the age of
59 years (range: 24–75 years)(figure 1).
Among 512 healthy central Europeans, 14% were
homozygous for SNP309 G, and in the cohort of 311 cen-
tral European patients diagnosed with NHL, 19% were
homozygous; the genotype frequencies did not deviate
from those expected under the Hardy-Weinberg equilib-
rium. Stratification according to SNP309 T/G genotypes
NHL and DLBCL cumulative distribution of age of onset for men (triangles) and women (diamonds) Figure 1
NHL and DLBCL cumulative distribution of age of onset for men (triangles) and women (diamonds). Age of 
onset was compared between male and female patients using the Mann-Whitney U test.
Cumulative distribution of age of onsetBMC Cancer 2008, 8:116 http://www.biomedcentral.com/1471-2407/8/116
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failed to reveal differences in the onset of NHL by age in
men (p = 0.25) and women (p = 0.29), and also in the
onset of DLBCL by age in men (p = 0.19) and women (p
= 0.82) (figure 2). Similar genotype frequencies were
observed in the controls and the male NHL and DLBCL
patient groups (figure 3). Previous work by Bond and col-
leagues had indicated that estrogen signalling can co-
operate with the G-allele of SNP309 in lymphomagenesis
in women, documented by stratification of the cohort in
pre-menopausal women up to 51 years and older women
[11]. In our study, no significant difference was detected
between female NHL or DLBCL patients diagnosed by 51
years of age and those diagnosed later (figure 3A). Specif-
ically, among all NHL patients, four of 31 women diag-
nosed by 51 years, and 26 of 105 women diagnosed later,
exhibited the G/G genotype (p = 0.35). For women diag-
nosed with DLBCL, these numbers were 3/20 and 19/70,
respectively (p = 0.59).
Next, we examined whether SNP309 T/G can influence
prognosis. For this purpose, Kaplan-Meier plots for EFS
and OS, stratified according to genotypes, were calculated
(figure 4A). Cox proportional hazard analysis to adjust for
IPI-factors (age >60; ex. involvement >1; ECOG 2–4; Stage
III-IV; LDH > ONV) and bulky disease showed no differ-
ence between the genotype groups G/G and T/T. (An inde-
pendent influence of SNP309 T/G on EFS/OS could not
be detected in this multivariate analysis). The results of
the Cox regression analyses are summarized in Table 3.
p53 gene SNP72 G/C
The allelic frequencies of the p53 gene SNP72 G/C poly-
morphism have been reported to vary widely between the
ethnicities [20]. For European/North American Cauca-
sians the frequency of the minor (C) allele coding for pro-
line at position 72 was between 22 and 30% in the various
studies, comparable with the frequency observed in our
controls (26%) [21], and references therein). Among the
patients diagnosed with NHL or DLBCL, the C allele was
found with a frequency of 25%, respectively. Again, all
genotype frequencies were as expected under the Hardy-
Weinberg equilibrium.
Since it was conceivable that our female patients ≤ 51
years of age at the time of diagnosis, instead of having a
reduced p53 response due to the SNP309 G/G genotype as
was observed in the Ashkenazi Jewish cohort [11], have an
apoptosis-impaired p53 associated with the SNP72 C/C
genotype [22], we analyzed the SNP72 genotype frequen-
cies by the same methods. No significant difference was
detected between female NHL or DLBCL patients diag-
nosed by 51 years of age and those diagnosed later (figure
3B). Specifically, in the NHL group, two of 31 women
diagnosed by 51 years and three of 105 women diagnosed
later, exhibited the C/C genotype. For women diagnosed
with DLBCL, these numbers were 2/20 and 2/70, respec-
tively.
Finally, we examined whether SNP72 G/C has an influ-
ence on prognosis. Kaplan-Meier plots were calculated for
EFS and OS, stratified according to genotypes (figure 4B).
Cox proportional hazard analysis to adjust for IPI-factors
(age >60; ex. involvement >1; ECOG 2–4; Stage III-IV;
LDH > ONV) and bulky disease showed no difference
between the genotype groups C/C and G/G. (Again, an
independent influence of SNP72 G/C on EFS/OS could
not be detected in this multivariate analysis). The results
of the Cox regression analyses are summarized in Table 3.
Discussion
The levels of the p53 tumor suppressor are primarily con-
trolled by the E3 ubiquitin ligase MDM2 [1]. MDM2 pro-
moter polymorphism SNP309 G gives rise to higher levels
of MDM2 in response to stress or estrogen, and conse-
quently, inhibits p53 more efficiently than SNP309 T
[8,10]. Several studies have implicated estrogen signalling
manipulation in cancer incidence and progression
(reviewed in [23]), and in gender-specific differences in
DLBCL incidence (for example, [24]). In accord with these
findings, Bond and colleagues have recently reported that
women homozygous for SNP309 G were diagnosed with
DLBCL on average 13 years earlier than women
homozygous for the T allele (G/G women: 55 years; T/T
women, 68 years), whereas men did not show such a cor-
relation. They also documented that the G/G genotype is
significantly more frequent among women diagnosed
before menopause (10/21 G/G-individuals were diag-
nosed by age 51 vs. 0/21 T/T-individuals; 11/58 G/G
women were diagnosed by age >51 vs. 13/58 T/T women),
and suggested that estrogen may co-operate with the G
allele to accelerate lymphoma formation [11]. These find-
ings could not be confirmed by our study; we observed
only 3/20 G/G women diagnosed by age 51. In this con-
text it should be noted that Bond et al. observed 24% G/
G homozygotes among 976 healthy Caucasians of
Ashkenazi Jewish descent, whereas we observed 14% in
our healthy cohort of 512 central European Caucasians.
Thus and in accord with these authors, Ashkenazi Jewish
Caucasians have a significantly higher SNP309 G/G geno-
type frequency than Non-Ashkenazi Caucasians from cen-
tral Europe (p < 0.001; Fisher's exact test).
MDM2 SNP309 T/G has originally been reported to be
associated with an increased risk for tumor formation in
patients with an inherited mutated p53 allele (Li-Frau-
meni syndrome) and in patients with sporadic soft tissue
sarcoma [10]. It should be kept in mind though that
MDM2 is a pleiotropic E3 ubiquitin ligase with many cel-
lular targets besides p53, one of the latest on the list being
topoisomerase II [25]. SNP309 might therefore affect sev-BMC Cancer 2008, 8:116 http://www.biomedcentral.com/1471-2407/8/116
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NHL and DLBCL cumulative distribution of age of onset for males and females with the SNP309 G/G or T/T genotype Figure 2
NHL and DLBCL cumulative distribution of age of onset for males and females with the SNP309 G/G or T/T 
genotype. Age of onset was compared between male and female patients using the Mann-Whitney U test.
Cumulative distribution of age of onset NHL
Cumulative distribution of age of onset DLBCL
Women
WomenBMC Cancer 2008, 8:116 http://www.biomedcentral.com/1471-2407/8/116
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eral cancer-relevant pathways. Homozygosity for SNP309
G has been linked to a significantly earlier onset of several
hereditary and sporadic cancers, including breast carcino-
mas and osteosarcomas, but also to DLBCL, adult soft tis-
sue sarcoma, invasive ductal breast cancer, and colorectal
cancer specifically in women. The polymorphism has fur-
thermore been associated with uterine leiomyosarcoma,
squamous cell carcinoma of the head and neck, the out-
come of breast cancer, non-small cell lung cancer, hepato-
cellular carcinoma in patients with chronic hepatitis C,
gastric carcinoma, esophageal squamous cell carcinoma,
nasopharyngeal carcinoma, ovarial carcinoma, sporadic
endometrial cancer, invasive bladder cancer, and renal
cell carcinoma (for a recent review, see [8]). However,
other studies fail to show an association. For instance, age
of onset of colorectal cancer in Lynch syndrome, lung can-
cer risk in a Chinese population, lung cancer risk, inci-
dence of breast cancer in mutant BRCA1 carriers,
incidence of breast and ovarian cancer, breast cancer risk
in a Chinese population, breast cancer risk, age at diagno-
sis of HNPCC patients, basal cell carcinoma risk, risk and
prognosis of glioblastoma (reviewed in [8]), and finally
NHL and DLBCL in Non-Ashkenazi European Caucasians
(this study), were not associated with SNP309. This
together with the discrepancy between our findings and
that of Bond and colleagues on DLBCL [11], points to the
importance of other genetic modifiers in the p53 path-
way.
Since its first description 20 years ago, hundreds of studies
on the p53 gene SNP72 polymorphism and cancer suscep-
tibility have been completed. Positive correlations were
reported, for instance, for hepatocellular carcinoma [26],
non-polyposis hereditary colorectal cancer [27,28],
nasopharyngeal carcinoma [29], and melanoma [30].
Recent meta-analyses found positive correlations of the C/
C genotype with gastric cancer in Asians [31], esophageal
cancer [32], and overall cancer mortality [33]. By contrast,
other meta-analyses failed to find a correlation with lung
cancer [34] and breast cancer [20]. No correlation was
also found for acute myelogenous leukaemia [35] and for
multiple myeloma, except when studied in combination
with other polymorphisms [36]. Likewise, our study on
patients with NHL and DLBCL failed to establish a corre-
lation with SNP72 G/C. Neither MDM2 gene SNP309 T/G
nor p53 gene SNP72 G/C influences diffuse-large B-cell
lymphoma in central European Caucasians.
Conclusion
We found no evidence that MDM2 gene SNP309 or p53
gene SNP72 is associated with an increased risk for, or
accelerated formation of, diffuse-large B-cell lymphoma
in men or women of central European Caucasian ethnic-
ity. Furthermore, neither SNP309 nor SNP72 was corre-
lated with age of onset, diagnosis, or survival of patients.
These polymorphisms may thus act as genetic modifiers
in dependence of a population genetic background.
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Kaplan-Meier plots for EFS and OS for the MDM2-SNP309 genotypes (A) and the p53 SNP 72 genotypes (B) in all NHL- patients Figure 4
Kaplan-Meier plots for EFS and OS for the MDM2-SNP309 genotypes (A) and the p53 SNP 72 genotypes (B) in 
all NHL-patients.
A
BBMC Cancer 2008, 8:116 http://www.biomedcentral.com/1471-2407/8/116
Page 9 of 10
(page number not for citation purposes)
Acknowledgements
This study was supported by grants from the German Research Foundation 
(DFG), Krebshilfe, and HOMFOR to MP and KR. MK is supported by a pre-
doctoral grant (GRK 1034) from the Georg August University of Göttingen 
(Germany).
References
1. Bond GL, Hu W, Levine AJ: MDM2 is a central node in the p53
pathway: 12 years and counting.  Curr Cancer Drug Targets 2005,
5:3-8.
2. Mendrysa SM, O'Leary KA, McElwee MK, Michalowski J, Eisenman
RN, Powell DA, Perry ME: Tumor suppression and normal aging
in mice with constitutively high p53 activity.  Genes Dev 2006,
20:16-21.
3. Jones SN, Roe AE, Donehower LA, Bradley A: Rescue of embry-
onic lethality in Mdm2-deficient mice by absence of p53.
Nature 1995, 378:206-208.
4. Montes de Oca Luna R, Wagner DS, Lozano G: Rescue of early
embryonic lethality in mdm2-deficient mice by deletion of
p53.  Nature 1995, 378:203-206.
5. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B: Ampli-
fication of a gene encoding a p53-associated protein in
human sarcomas.  Nature 1992, 358:80-83.
6. Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE,
Sidransky D, Kinzler KW, Vogelstein B: p53 Mutation and MDM2
amplification in human soft tissue sarcomas.  Cancer Res 1993,
53:2231-2234.
7. Freedman DA, Levine AJ: Regulation of the p53 protein by the
MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial
Award Lecture.  Cancer Res 1999, 59:1-7.
8. Bond GL, Levine AJ: A single nucleotide polymorphism in the
p53 pathway interacts with gender, environmental stresses
and tumor genetics to influence cancer in humans.  Oncogene
2007, 26:1317-1323.
9. Kinyamu HK, Archer TK: Estrogen receptor-dependent protea-
somal degradation of the glucocorticoid receptor is coupled
to an increase in mdm2 protein expression.  Mol Cell Biol 2003,
23:5867-5881.
10. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargon-
etti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong
LC, Lozano G, Levine AJ: A single nucleotide polymorphism in
the MDM2 promoter attenuates the p53 tumor suppressor
pathway and accelerates tumor formation in humans.  Cell
2004, 119:591-602.
11. Bond GL, Hirshfield KM, Kirchhoff T, Alexe G, Bond EE, Robins H,
Bartel F, Taubert H, Wuerl P, Hait W, Toppmeyer D, Offit K, Levine
AJ: MDM2 SNP309 accelerates tumor formation in a gender-
specific and hormone-dependent manner.  Cancer Res 2006,
66:5104-5110.
12. Bond GL, Menin C, Bertorelle R, Alhopuro P, Aaltonen LA, Levine AJ:
MDM2 SNP309 accelerates colorectal tumour formation in
women.  J Med Genet 2006, 43:950-2. Epub 2006 Jul 6..
13. p53-knowledgebase:  [http://p53.bii.astar.edu.sg/aboutp53/snps/snp-
detail.php?geneid=X54156&snppos=12139].
14. Hong Y, Miao X, Zhang X, Ding F, Luo A, Guo Y, Tan W, Liu Z, Lin
D: The role of P53 and MDM2 polymorphisms in the risk of
esophageal squamous cell carcinoma.  Cancer Res 2005,
65:9582-9587.
15. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rube C,
Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D,
Schmitz N, Loeffler M: Two-weekly or 3-weekly CHOP chemo-
therapy with or without etoposide for the treatment of eld-
erly patients with aggressive lymphomas: results of the
NHL-B2 trial of the DSHNHL.  Blood 2004, 104:634-41. Epub
2004 Mar 11..
16. Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller AC, Rudolph
C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N,
Glass B, Rube C, Loeffler M: Two-weekly or 3-weekly CHOP
chemotherapy with or without etoposide for the treatment
of young patients with good-prognosis (normal LDH) aggres-
sive lymphomas: results of the NHL-B1 trial of the DSH-
NHL.  Blood 2004, 104:626-33. Epub 2004 Feb 24..
17. Boltze C, Roessner A, Landt O, Szibor R, Peters B, Schneider-Stock
R: Homozygous proline at codon 72 of p53 as a potential risk
factor favoring the development of undifferentiated thyroid
carcinoma.  Int J Oncol 2002, 21:1151-1154.
18. Pont-Kingdon G, Lyon E: Direct molecular haplotyping by melt-
ing curve analysis of hybridization probes: beta 2-adrenergic
receptor haplotypes as an example.  Nucleic Acids Res 2005,
33:e89..
19. Ihaka R, Gentleman RR: A language for data analysis and graph-
ics.  J Comp Graph Statistics 1996, 5:299-314.
20. Weston A, Godbold JH: Polymorphisms of H-ras-1 and p53 in
breast cancer and lung cancer: a meta-analysis.  Environ Health
Perspect 1997, 105:919-926.
21. Pietsch EC, Humbey O, Murphy ME: Polymorphisms in the p53
pathway.  Oncogene 2006, 25:1602-1611.
22. Dumont P, Leu JI, Della Pietra AC 3rd, George DL, Murphy M: The
codon 72 polymorphic variants of p53 have markedly differ-
ent apoptotic potential.  Nat Genet 2003, 33:357-65. Epub 2003
Feb 3..
23. Dietel M, Lewis MA, Shapiro S: Hormone replacement therapy:
pathobiological aspects of hormone-sensitive cancers in
Table 3: Cox regression adjusted for IPI-factors and bulky disease
MDM2 gene SNP309
event-free survival overall survival
G/G vs. G/T and T/T T/T vs. G/T and G/G G/G vs. G/T and T/T T/T vs. G/T and G/G
DLBC samples 1.20 (0.71;2.01) 0.95 (0.61;1.48) 1.19 (0.65;2.18) 0.81 (0.48;1.38)
all samples: 0.98 (0.63;1.52) 1.21 (0.86;1.72) 0.98 (0.59;1.64) 0.99 (0.66;1.48)
relative risk with 95% confidence interval
p53 gene SNP72
event-free survival overall survival
Arg/Arg vs. Arg/Pro and Pro/Pro Pro/Pro vs. Arg/Pro and Arg/Arg Arg/Arg vs. Arg/Pro and Pro/Pro Pro/Pro vs. Arg/Pro and Arg/Arg
DLBC samples 1.06 (0.69;1.65) 1.31 (0.40;4.30) 1.13 (0.68;1.88) 1.60 (0.37;6.90)
all samples: 0.93 (0.66;1.31) 1.45 (0.63;3.30) 0.99 (0.66;1.47) 1.41 (0.51;3.87)
relative risk with 95% confidence intervalBMC Cancer 2008, 8:116 http://www.biomedcentral.com/1471-2407/8/116
Page 10 of 10
(page number not for citation purposes)
women relevant to epidemiological studies on HRT: a mini-
review.  Hum Reprod 2005, 20:2052-60. Epub 2005 Jun 2..
24. Nelson RA, Levine AM, Bernstein L: Reproductive factors and
risk of intermediate- or high-grade B-Cell non-Hodgkin's
lymphoma in women.  J Clin Oncol 2001, 19:1381-1387.
25. Nayak MS, Yang JM, Hait WN: Effect of a single nucleotide poly-
morphism in the murine double minute 2 promoter
(SNP309) on the sensitivity to topoisomerase II-targeting
drugs.  Cancer Res 2007, 67:5831-5839.
26. Yu MW, Yang SY, Chiu YH, Chiang YC, Liaw YF, Chen CJ: A p53
genetic polymorphism as a modulator of hepatocellular car-
cinoma risk in relation to chronic liver disease, familial ten-
dency, and cigarette smoking in hepatitis B carriers.
Hepatology 1999, 29:697-702.
27. Jones JS, Chi X, Gu X, Lynch PM, Amos CI, Frazier ML: p53 poly-
morphism and age of onset of hereditary nonpolyposis color-
ectal cancer in a Caucasian population.  Clin Cancer Res 2004,
10:5845-5849.
28. Kruger S, Bier A, Engel C, Mangold E, Pagenstecher C, von Knebel
Doeberitz M, Holinski-Feder E, Moeslein G, Schulmann K, Plaschke J,
Ruschoff J, Schackert HK: The p53 codon 72 variation is associ-
ated with the age of onset of hereditary non-polyposis color-
ectal cancer (HNPCC).  J Med Genet 2005, 42:769-773.
29. Tsai MH, Lin CD, Hsieh YY, Chang FC, Tsai FJ, Chen WC, Tsai CH:
Prognostic significance of the proline form of p53 codon 72
polymorphism in nasopharyngeal carcinoma.  Laryngoscope
2002, 112:116-119.
30. Stefanaki I, Stratigos AJ, Dimisianos G, Nikolaou V, Papadopoulos O,
Polydorou D, Gogas H, Tsoutsos D, Panagiotou P, Kanavakis E, Anto-
niou C, Katsambas AD: p53 codon 72 Pro homozygosity
increases the risk of cutaneous melanoma in individuals with
dark skin complexion and among noncarriers of melanocor-
tin 1 receptor red hair variants.  Br J Dermatol 2007, 156:357-362.
31. Zhou Y, Li N, Zhuang W, Liu GJ, Wu TX, Yao X, Du L, Wei ML, Wu
XT: P53 codon 72 polymorphism and gastric cancer: A meta-
analysis of the literature.  Int J Cancer 2007, 121:1481-1486.
32. Hiyama T, Yoshihara M, Tanaka S, Chayama K: Genetic polymor-
phisms and esophageal cancer risk.  Int J Cancer 2007,
121:1643-1658.
33. van Heemst D, Mooijaart SP, Beekman M, Schreuder J, de Craen AJ,
Brandt BW, Slagboom PE, Westendorp RG: Variation in the
human TP53 gene affects old age survival and cancer mortal-
ity.  Exp Gerontol 2005, 40:11-15.
34. Matakidou A, Eisen T, Houlston RS: TP53 polymorphisms and
lung cancer risk: a systematic review and meta-analysis.
Mutagenesis 2003, 18:377-385.
35. Zhang W, Hu G, Deisseroth A: Polymorphism at codon 72 of the
p53 gene in human acute myelogenous leukemia.  Gene 1992,
117:271-275.
36. Ortega MM, Honma HN, Zambon L, Lorand-Metze I, Costa FF, De
Souza CA, Lima CS: GSTM1 and codon 72 P53 polymorphism
in multiple myeloma.  Ann Hematol 2007, 86:815-819.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/116/pre-
pub